VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RAPP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RAPPRapport Therapeutics, Inc. Common Stock
$23.40$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksRAPPBalance Sheet

Rapport Therapeutics, Inc. Common Stock (RAPP) Balance Sheet

4Y historyFree accessUpdated daily

Leverage is minimal with total debt of $9.4M against $391.2M of equity (debt-to-equity 0.02), yet the accumulated deficit of -$351.9M and a shrinking equity base suggest the capital cushion is being steadily consumed by clinical spend.

Income StatementBalance SheetCash FlowRatios

RAPP Balance Sheet

Annual statement

RAPP Balance Sheet

Rapport Therapeutics, Inc. Common Stock (RAPP) balance sheet — 4-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22
Total Current Assets407.38M498.56M309.8M150.87M31.27M
Cash & Short-Term Investments395.03M490.54M305.28M147.48M31.16M
Cash Only74.75M52.65M56.8M70.17M31.16M
Short-Term Investments320.27M437.89M248.47M77.31M0
Accounts Receivable171K0000
Days Sales Outstanding2.38----
Inventory00000
Days Inventory Outstanding-----
Other Current Assets105K8.02M4.52M3.39M0
Total Non-Current Assets11.18M13.87M5.13M4.55M335K
Property, Plant & Equipment10.08M12.88M4.97M4M335K
Fixed Asset Turnover1.74x----
Goodwill00000
Intangible Assets00000
Long-Term Investments00000
Other Non-Current Assets1.09M985K160K551K0
Total Assets418.56M512.43M314.93M155.42M31.6M
Asset Turnover0.04x----
Asset Growth %166.4%62.71%102.63%391.8%-
Total Current Liabilities20.3M19.05M8.77M8.8M1.66M
Accounts Payable1.72M4.19M1.95M2.5M1.45M
Days Payables Outstanding----35.28K
Short-Term Debt00000
Deferred Revenue (Current)00000
Other Current Liabilities07.12M3.71M2.41M0
Current Ratio20.07x26.17x35.34x17.14x18.80x
Quick Ratio20.07x26.17x35.34x17.14x18.80x
Cash Conversion Cycle2.38----
Total Non-Current Liabilities7.07M8.73M739K172.25M10.44M
Long-Term Debt08.73M0010.44M
Capital Lease Obligations14.7M0739K1.48M0
Deferred Tax Liabilities00000
Other Non-Current Liabilities000170.78M0
Total Liabilities27.37M27.78M9.51M181.06M12.1M
Total Debt9.39M11.48M1.48M2.15M10.44M
Net Debt-65.36M-41.16M-55.33M-68.02M-20.72M
Debt / Equity0.02x0.02x0.00x-0.53x
Debt / EBITDA-0.06x----
Net Debt / EBITDA0.39x----
Interest Coverage-----36.38x
Total Equity391.19M484.65M305.43M-25.63M19.5M
Equity Growth %160.6%58.68%1291.49%-231.42%-
Book Value per Share8.1912.4514.73-17.020.97
Total Shareholders' Equity391.19M484.65M305.43M-25.63M19.5M
Common Stock48K48K37K4K31K
Retained Earnings-351.94M-235.23M-123.75M-45.44M-10.65M
Treasury Stock00000
Accumulated OCI-2.12M546K-522K4K0
Minority Interest00000

Key Metrics

Growth RegimeStable
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Dilution dependence through pivotal trials

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Base Shrinking as Losses Accumulate

According to reported balance sheet figures, RAPP's total equity fell from $423M in 2025Q4's neighbor 2026Q2 level to $391.2M in 2026Q3 as accumulated deficit deepened to -$351.9M, signaling steady erosion of the capital base.

The balance sheet appears to be weakening rather than strengthening, with equity declining in each of the most recent quarters while the accumulated deficit widens in step with R&D-driven losses. This pattern suggests the company is consuming its equity cushion faster than it can be replenished through operations, which is expected for a pre-revenue firm but still warrants monitoring of how much runway remains before the next capital raise. Investors should watch whether the decline continues at the pace implied by the recent quarterly losses.

Thin Cash Cushion Against Quarterly Burn

As reported in the financial statements, RAPP held $74.8M in cash at 2026Q3 against an operating cash outflow of $41.6M in the same quarter, implying coverage of only about two quarters at current burn rates.

The current ratio of 20.07 looks strong on the surface, but it is driven by a largely liquid asset base that is being drawn down rapidly by clinical spending rather than reflecting durable financial strength. The cash position relative to quarterly outflows suggests limited tolerance for trial delays or cost overruns. This may indicate that a financing event is a plausible near-term outcome rather than a remote contingency.

Minimal Leverage Keeps Solvency Risk Low

Based on reported figures, RAPP carries total debt of just $9.4M against $391.2M of equity, producing a debt-to-equity ratio of 0.02 that leaves the company largely insulated from creditor pressure.

Leverage is negligible and appears deliberate, consistent with an equity-funded development model rather than a necessity-driven borrowing pattern. Because debt is so small, refinancing risk is minimal and near-term solvency is not the binding constraint. The real pressure point is equity funding, not debt service, which shifts the risk toward dilution.

Accumulated Deficit Signals Dilution Path

According to reported equity figures, retained earnings stood at -$351.9M in 2026Q3, and the company's reliance on external capital means shareholders should expect further issuance as pivotal trial costs ramp.

The deepening accumulated deficit reflects the cumulative cost of clinical development rather than any recurring value leakage, but it also means the equity base is being funded almost entirely by outside capital. Continued losses of roughly $40M per quarter imply that additional share issuance is a likely path, with corresponding dilution for existing holders. Stock-based compensation of around $7.6M per quarter adds a further non-cash claim on equity that investors should factor into per-share economics.

Headline Cash Overstates Usable Runway

Based on reported figures, the balance sheet may look more secure than the cash burn warrants, since $74.8M in cash measured against recent quarterly outflows of $41.6M suggests the effective runway could be shorter than headline liquidity implies.

The most non-obvious distortion is that a strong current ratio and near-zero leverage can mask a short effective runway, because the liquid assets are small relative to the pace of clinical spending. Cash balances also swing meaningfully quarter to quarter, as seen in the drop from $251.4M in 2025Q3 to $52.6M in 2025Q4, which indicates that reported liquidity levels can change sharply. Analysts should therefore treat the balance sheet as adequate only until the next financing, not as a durable buffer.

RAPP — Frequently Asked Questions

Quick answers to the most common questions about buying RAPP stock.

What are the total assets of Rapport Therapeutics, Inc. Common Stock (RAPP)?

As of 2025, Rapport Therapeutics, Inc. Common Stock (RAPP) had total assets of $512.4M including $498.6M in current assets.

How much debt does Rapport Therapeutics, Inc. Common Stock (RAPP) have?

Rapport Therapeutics, Inc. Common Stock (RAPP) carries total debt of $11.5M, offset by $490.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Rapport Therapeutics, Inc. Common Stock?

Rapport Therapeutics, Inc. Common Stock (RAPP) has total shareholders' equity (book value) of $484.7M ($12.45 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Rapport Therapeutics, Inc. Common Stock's current ratio and liquidity?

Rapport Therapeutics, Inc. Common Stock (RAPP) reported a current ratio of 26.17x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.